An approved Investigational Device Exemption (IDE) is required to allow use of an investigational device in a clinical study to collect safety and efficacy data to support a Premarket Approval (PMA) application. More information about the IDE process is available from the FDA website: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/default.htmABOUT CERUS Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the proposed Phase III INTERCEPT red cell system trial, the therapeutic and commercial potential of the INTERCEPT red cell system, and future regulatory matters, including those related to the IDE process with the FDA, the number and scope of additional studies required prior to initiating the proposed Phase III INTERCEPT red cell system trial, and potential regulatory approval. These forward-looking statements are based upon Cerus’ current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with the uncertain clinical development and regulatory approval process, including the risks that Cerus’ IDE application may not be reviewed or approved by the FDA in a timely manner or at all, that the FDA may require that we conduct additional unanticipated clinical studies to initiate Phase III development of the INTERCEPT red cell system and/or to support potential approval of INTERCEPT red cells, and that we may never obtain FDA approval of INTERCEPT red cells, risks associated with Cerus’ need for additional capital, including the risk that Cerus may be unable to raise the funds necessary to conduct the proposed Phase III INTERCEPT red cell system trial or any other trials of the INTERCEPT red cell system required by the FDA, and other risks detailed in the Cerus' filings with, the Securities and Exchange Commission (SEC), including in Cerus' annual report on Form 10-K for the year ended December 31, 2011, filed with the SEC on March 5, 2011. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.